Medicines Co (The) (MDCO)
Medicines is a biopharmaceutical company. Co. is focused on inclisiran, the investigational RNA interference therapeutic, that inhibits production of proprotein convertase subtilisin/kexin type 9, a main protein that controls low-density lipoprotein-cholesterol levels. Co. has the right to develop, manufacture and commercialize inclisiran under its collaboration agreement with Alnylam Pharmaceuticals, Inc.
|
April 19, 2024 2:59 PM Eastern
Hold (2.44 out of 4)
100th percentile
|
|